Back to Search
Start Over
FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine
- Source :
- BMC Medical Genetics, BMC Medical Genetics, Vol 19, Iss 1, Pp 1-7 (2018)
- Publication Year :
- 2018
- Publisher :
- Springer Science and Business Media LLC, 2018.
-
Abstract
- Background FANCM and RECQL have recently been reported as breast cancer susceptibility genes and it has been suggested that they should be included on gene panel tests for breast cancer predisposition. However, the clinical value of testing for mutations in RECQL and FANCM remains to be determined. In this study, we have characterised the spectrum of FANCM and RECQL mutations in women affected with breast or ovarian cancer from South-West Poland and West Ukraine. Methods We applied Hi-Plex, an amplicon-based enrichment method for targeted massively parallel sequencing, to screen the coding exons and proximal intron-exon junctions of FANCM and RECQL in germline DNA from unrelated women affected with breast cancer (n = 338) and ovarian cancer (n = 89) from Poland (n = 304) and Ukraine (n = 123). These women were at high-risk of carrying a genetic predisposition to breast and/or ovarian cancer due to a family history and/or early-onset disease. Results Among 427 women screened, we identified one carrier of the FANCM:c.1972C > T nonsense mutation (0.23%), and two carriers of the frameshift insertion FANCM:c.1491dup (0.47%). None of the variants we observed in RECQL were predicted to be loss-of-function mutations by standard variant effect prediction tools. Conclusions Our study of the Polish and Ukrainian populations has identified a carrier frequency of truncating mutations in FANCM consistent with previous reports. Although initial reports suggesting that mutations in RECQL could be associated with increased breast cancer risk included women from Poland and identified the RECQL:c.1667_1667 + 3delAGTA mutation in 0.23–0.35% of breast cancer cases, we did not observe any carriers in our study cohort. Continued screening, both in research and diagnostic settings, will enable the accumulation of data that is needed to establish the clinical utility of including RECQL and FANCM on gene panel tests. Electronic supplementary material The online version of this article (10.1186/s12881-018-0524-x) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
Oncology
medicine.disease_cause
0302 clinical medicine
FANCM
Gene Frequency
Risk Factors
Gene panel testing
Genetics (clinical)
Aged, 80 and over
Ovarian Neoplasms
Mutation
RecQ Helicases
medicine.diagnostic_test
Exons
Middle Aged
Pedigree
3. Good health
RECQL
Codon, Nonsense
030220 oncology & carcinogenesis
Female
Familial breast cancer
Ukraine
Research Article
Adult
lcsh:Internal medicine
medicine.medical_specialty
lcsh:QH426-470
Nonsense mutation
Breast Neoplasms
White People
Frameshift mutation
Young Adult
03 medical and health sciences
Breast cancer
Internal medicine
Genetics
medicine
Genetic predisposition
Humans
Genetic Predisposition to Disease
lcsh:RC31-1245
Aged
Genetic testing
business.industry
DNA Helicases
Genetic Variation
Cancer
medicine.disease
lcsh:Genetics
Breast cancer predisposition
030104 developmental biology
Case-Control Studies
Poland
business
Subjects
Details
- ISSN :
- 14712350
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- BMC Medical Genetics
- Accession number :
- edsair.doi.dedup.....7b154d522dd29c7bb427ef1bc1bfe9e5
- Full Text :
- https://doi.org/10.1186/s12881-018-0524-x